BioCentury
ARTICLE | Clinical News

Farletuzumab: Preliminary Phase III data

January 21, 2013 8:00 AM UTC

Preliminary data from the double-blind, international Phase III Study FAR 131 (MORAb-003-004) trial in 1,100 patients with platinum-sensitive epithelial ovarian cancer in first relapse showed that IV farletuzumab plus carboplatin and taxane chemotherapy missed the primary endpoint of improving PFS vs. placebo plus carboplatin and taxane chemotherapy. Eisai also said a post hoc exploratory analysis showed a trend toward improved PFS in undisclosed patient subgroups. Patients received carboplatin and taxane chemotherapy plus placebo or once-weekly 1.25 or 2.5 mg/kg farletuzumab for 6 cycles. Eisai said it will determine a new development strategy for farletuzumab in ovarian cancer based on discussion with external experts and health authorities. ...